GBA's "2021 Stock Phantasma"

Discussion in 'Stocks' started by stonedinvestor, Jan 1, 2021.

  1. vanzandt

    vanzandt

    I looked in Miami
    I looked in Negril
    The closest I came...
    ....was a month old bill

    ....Sunspot baby
    She sure had a real good time
     
    Last edited: Jun 24, 2021
    #6251     Jun 24, 2021
  2. $22----> $26
    GMVHY
    Entain Plc
    $26.06
    0.67(+2.62%)

    Vs.

    Elys Game Technology, Corp. (ELYS)
    $4.91----> $4.30


    4.3400+0.0200 (+0.46%)
    At close: June 24 4:00PM EDT
     
    #6252     Jun 25, 2021
  3. Dear Mr Mizuho.-

    I am reminded of what you told me when we first met. If you don't leave a saucer of milk the kitten won't come. You know how this works. Your price target on Marqeta is a foolish move on your part. We all have come to terms with the reliance on Square, there is nothing new there, you avoided the Crypto angle completely. We are very disappointed in your analysis if you can call it that. ~GBA
     
    #6253     Jun 25, 2021
  4. Only Leidos can get a near 1 billion contract & not move!

    Leidos awarded $950M prime contract by U.S. Air Force 08:03 LDOS
     
    #6254     Jun 25, 2021
    vanzandt likes this.
  5. vanzandt

    vanzandt

    What's that about?
    Someone downgrade it?

    Hey Stoney I have a new one.
    IPO.
    Biotech.
    Hallucinogenics.
    Backed by Peter T.

    ATAI
    $18
    German operation.

    Peter Thiel-Backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
    Natan Ponieman, Benzinga
    Jun. 18, 2021, 05:02 PM


    Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday.

    The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sector to IPO this year on the Nasdaq, including MindMed (NASDAQ:MNMD) and Compass Pathways (NASDAQ:CMPS).

    Initially founded as a holding group that later became involved in operations, Atai handles a growing portfolio of about 12 companies, all focused on bringing novel mental health treatments through the use of various disruptive technologies and molecules including psychedelic medicines.

    Its portfolio includes Perception Neurosciences, a company putting ketamine through clinical trials for the treatment of depression, as well as other companies developing psychedelics like MDMA, ibogaine and DMT for mental health purposes.

    Atai is also a major shareholder in Compass Pathways, a company developing psilocybin products for psychedelics-assisted psychotherapy, which was the first psychedelics company to debut on Wall Street in September 2020.
     
    #6255     Jun 25, 2021
  6. XAIR Vol-1,175,352
    Avg. Volume 419,507
     
    #6256     Jun 25, 2021
  7. That's the bio using ketamine. Peter Thiel probably dabbles a bit before investing in his ROTH IRA.....
     
    #6257     Jun 25, 2021
  8. GVA was about $40.60 at noon yesterday and then made a move.

    Now $42.20<--------
     
    #6258     Jun 25, 2021
  9. PSFE- Up 10%
    Paysafe Limited
    11.11
    -0.09(-0.80%)
    4:00 PM 06/24/21
    Pre-Market:$12.25+1.14(+10.26%)<--------
     
    #6259     Jun 25, 2021
  10. I hit the road 10:00-10:30 /
     
    #6260     Jun 25, 2021